Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors
Authors:
- 16 March 2020
- journal article
- research article
- Published by Wiley in Archiv der Pharmazie
- Vol. 353 (5) , e2000005
Abstract
Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. Research on structure–activity relationship resulted in a new derivative B4 that is capable of occupying both the p2 and p4 more deeply and completely than A1, with Ki values determined by fluorescence polarization assay (FPAs) improving to 0.31 μM for Bcl‐2 and 0.16 μM for Mcl‐1. Furthermore, B4 exhibited selective lethality on cancer cells over normal cells. It showed stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line and killed an Mcl‐1‐dependent cell line which is resistant to ABT‐199 treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81430083, 81570129, 81903462)
- China Postdoctoral Science Foundation (2018M641694)
This publication has 32 references indexed in Scilit:
- Design, synthesis and preliminary bioactivity studies of indomethacin derivatives as Bcl-2/Mcl-1 dual inhibitorsBioorganic & Medicinal Chemistry, 2019
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemiaLeukemia, 2018
- Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin AEuropean Journal of Medicinal Chemistry, 2018
- Targeting BCL-2-like Proteins to Kill Cancer CellsTrends in Cancer, 2016
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapyNature Reviews Molecular Cell Biology, 2013
- Deciphering the rules of programmed cell death to improve therapy of cancer and other diseasesThe EMBO Journal, 2011
- Mcl‐1; the molecular regulation of protein functionFEBS Letters, 2010
- Therapeutic targeting of apoptosis pathways in cancerCurrent Opinion in Oncology, 2008
- Prostatic ductal adenocarcinoma showing Bcl‐2 expressionInternational Journal of Urology, 2004
- Cell DeathCell, 2004